Nuvectis Pharma
NVCT
31 hedge funds and large institutions have $6.6M invested in Nuvectis Pharma in 2024 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 13 closing their positions.
0.94% less ownership
Funds ownership: 6.56% → 5.63% (-0.94%)
24% less funds holding
Funds holding: 41 → 31 (-10)
25% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 12
41% less capital inflows, than outflows
Capital inflows: $1.43M | Capital outflows: $2.42M
77% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Iridian Asset Management
Westport,
Connecticut
|
+$364K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$329K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$174K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$174K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$95.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$390K |
| 2 |
Renaissance Technologies
New York
|
-$386K |
| 3 |
Millennium Management
New York
|
-$335K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$227K |
| 5 |
BlackRock
New York
|
-$223K |
NVCT Hedge Fund Activity: Q3 2024 in Review
31 of the 6,987 institutional investors tracked by Wall St. Rank reported a position in Nuvectis Pharma (NVCT) for Q3 2024, worth a combined $6.6M — down 13% from $7.63M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of NVCT and 3 opened new positions — a net loss of 10 holders — while 12 trimmed existing stakes and 9 added.
The largest buyer was Iridian Asset Management, opening a new position worth an estimated $364K. The largest seller was Goldman Sachs, exiting entirely with an estimated $390K sold.
- 31 institutional investors held Nuvectis Pharma (NVCT) as of Q3 2024, down from 41 in Q2 2024.
- Funds reported $6.6M of Nuvectis Pharma stock for Q3 2024, down 13% quarter-over-quarter.
- 3 funds opened new Nuvectis Pharma positions in Q3 2024 and 13 closed out, a net change of -10 holders.
- The largest Nuvectis Pharma buyer in Q3 2024 was Iridian Asset Management, an estimated $364K added.
- The largest Nuvectis Pharma seller in Q3 2024 was Goldman Sachs, an estimated $390K sold.
Based on aggregated 13F filings for Q3 2024.